Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
rubber dildos.
Popular Articles

European Paediatric Influenza Analysis (EPIA) Group Formed To Quantify The Burden Of Seasonal Influenza In Children In Europe
The Netherlands Institute for Health Services Research (NIVEL) and SDI, a U.S. private-sector healthcare information company, announced the formation of the European Paediatric Influenza Analysis (EPIA) group, created to generate data needed to inform the decision process about paediatric influenza vaccination policy in individual European countries. Researchers from Denmark, England, Finland, Italy, the Netherlands, Scotland, Spain and Wales are participating; it is hoped that other countries will also join. EPIA was formed to address knowledge gaps highlighted in a recent European Centre for Disease Prevention and Control (ECDC) report that concluded that a key barrier to decision-making about paediatric flu vaccines is the lack of high-quality, European-specific data on disease burden, especially for young children. It is estimated by ECDC that at least 40,000 people die each year from influenza in the European Union (EU). EPIA will present the initial results from their research project at the 27th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID) in June.
diet pills
Johns Hopkins Patient Safety Program Receives Healthcare Informatics Magazine's 2009 Innovator Award
Johns Hopkins Medicine"s patient safety program has earned second place in Healthcare Informatics magazine"s eighth annual Innovator Awards.
News of the day
PPD Confirms Takeda Receives FDA Complete Response For Alogliptin
PPD, Inc. (NASDAQ: PPDI) today announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin.
Endocrinology

Boston Scientific Announces European Approval For Its Latitude(R) Patient Management System

Boston Scientific Corporation (NYSE: BSX) announced CE Mark for its LATITUDE® Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient"s heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient"s physician. It will be launched in Europe in a phased approach beginning this week. "The wireless LATITUDE system will enable me to more closely monitor my patients while helping manage hospital workflow," said Konstantin M. Heinroth, M.D., Department of Medicine, Martin Luther-University Halle-Wittenberg, Halle, Germany. "I hope to provide my patients added convenience and the peace of mind that comes from knowing both their device and heart health status can be monitored." "Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in the U.S. in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry[1]," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We expect continued success as we introduce the demonstrated benefits of our LATITUDE system to patients and physicians in Europe. Remote monitoring technology provides a significant opportunity to further improve patient care." The LATITUDE system provides physicians actionable information that enables them to see changes in their patient"s cardiac health sooner than regularly scheduled follow-up visits. LATITUDE is the only remote cardiac device monitoring system with an optional wireless weight scale and blood pressure monitor, both of which are recommended by the European Society of Cardiology for the management of Class I heart failure patients. The international version of the LATITUDE system is compatible with the Company"s wireless TELIGEN® implantable cardioverter defibrillator (ICD) and COGNIS® cardiac resynchronization therapy defibrillator (CRT-D), the world"s smallest and thinnest high-energy devices. The first enrollments of European patients onto the LATITUDE system were performed by Dr. J.H. Ruiter at Medisch Centrum Hospital, Alkmaar, Netherlands and Dr. Peter Mortensen, Skejby University Hospital, Aarhus, Denmark. [1] Data based on number of patients at three years post-launch. Data on file. Boston Scientific


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009